brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
orgovyx
accord healthcare s.l.u. - relugolix - blöðruhálskirtli - innkirtla meðferð - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - svefntruflun og viðhald - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
pyrukynd
agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.
norditropin flexpro stungulyf, lausn 5/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml
norditropin flexpro stungulyf, lausn 15/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml
norditropin flexpro stungulyf, lausn 10/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml
microgyn tafla
bayer ab* - levonorgestrelum inn; ethinylestradiolum inn - tafla
strefen honung & citron (strefen körsbär & mint) munnholsúði, lausn 16,2 mg/ml
reckitt benckiser healthcare (scandinavia) a/s - flurbiprofenum inn - munnholsúði, lausn - 16,2 mg/ml
navelbine mjúkt hylki 30 mg
pierre fabre pharma norden ab - vinorelbinum tvítartrat - mjúkt hylki - 30 mg